enVVeno Medical news
IRVINE, CA / August 16, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, today announced the appointment of Kevin Belteau as Vice President of Clinical Operations. Mr. Belteau joins enVVeno Medical following a twenty-three-year career in clinical operations at Medtronic.
Mr. Belteau joined Medtronic as a field engineer upon graduation from
Ended the quarter with $47.2 million in cash and investments – expected to fund operations through the end of 2024, including release of topline SAVVE pivotal trial data
IRVINE, CA / August 3, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, today provided a corporate update and reported financial results for the sec
- New Current Procedural Terminology (CPT®) III code establishes a reimbursement pathway for the VenoValve
- The VenoValve is a potential first-in-class treatment for patients suffering from Chronic Venous Insufficiency (CVI) of the deep veins of the leg
- There are currently no effective treatments for patients with deep venous CVI
- The VenoValve is currently being evaluated in leading hospitals thro
- Ended the quarter with $51.3 million in cash – expected to fund operations through the end of 2024 including release of topline pivotal trial data
- Ongoing advancement of SAVVE U.S pivotal trial with 20 sites available to enroll patients
- Progress on development of second device for the treatment of venous disease expected to be unveiled in mid-2022
IRVINE, CA / May 2, 2022 / enV
- Ended the Year With $55 Million in Cash Expected To Fund Operations Through the End of 2024 Including Release of Topline Pivotal Trial Data
- Nine (9) VenoValve Surgeries Successfully Completed and 16 Clinical Sites Currently Active in Ongoing SAVVE U.S Pivotal Trial
- Continued Advancement in Development of Second Device for the Treatment of Venous Disease Expected To Be Unveiled in Mid-2022